
INSP Stock Forecast & Price Target
INSP Analyst Ratings
Bulls say
Inspire Medical Systems Inc. demonstrates a positive outlook driven by a significant increase in volume at centers that have transitioned to their gen 5 system, achieving over a 20% increase in the first half of 2025 compared to the same period in 2024. The company's revenue growth is anticipated to accelerate by 12-13% year-over-year in FY2026, as management expects the impact of the gen 5 rollout and diminishing headwinds to enhance performance. Furthermore, a shift towards a favorable product mix will likely improve gross margins, providing additional leverage on profit and loss as the company expands its marketing efforts and patient awareness programs.
Bears say
Inspire Medical Systems Inc. has underperformed expectations for fiscal year 2025, primarily due to a slower-than-anticipated launch of the Inspire V system, leading the company to revise its revenue guidance downwards by $37.5 million at the midpoint. The revised earnings per share outlook has also seen a significant reduction, from a range of $2.20-$2.30 down to $0.40-$0.50, reflecting increased operational spending and lower revenue growth. Furthermore, the company's gross margin of 84.0% fell short of pre-call estimates, indicating additional operational challenges contributing to an overall impaired financial outlook.
This aggregate rating is based on analysts' research of Inspire Medical Systems Inc and is not a guaranteed prediction by Public.com or investment advice.
INSP Analyst Forecast & Price Prediction
Start investing in INSP
Order type
Buy in
Order amount
Est. shares
0 shares